Результаты поиска

A Hypochlorite-Activated Theranostic Prodrug for Selective Imaging of High Myeloperoxidase Expression Acute Myeloid Leukemia Cells and Drug Release.

Acute myeloid leukemia (AML) is a fatal hematologic disease. Diagnosis and proper treatment are important for prognosis. High myeloperoxidase (MPO) expression AML cells are characterized with high levels of hypochlorite (ClO-). In this study, we report a ClO--activated theranostic agent, FNC, for AML therapy. FNC responds to ClO- specifically in high MPO expression AML cells, resulting in bright fluorescence and chlorambucil release. FNC can be used to quickly distinguish high MPO expression AML cells from other cells, including low MPO expression leukemia and activated inflammatory cells. FNC…

Behçet's disease in Moroccan children: a report of 12 cases.

We report 12 cases of Behçet's disease (BD) in children. The mean age of symptom onset was 12.4 years. Four patients (33.3%) had a past familial history of BD. Clinical manifestations were: oral aphtosis (n = 12), genital aphtosis (n = 9), ocular involvement (n = 9), neuro-Behçet (n = 6), venous thrombosis (n = 4), articular involvement (n = 3), and entero-Behçet (n = 1). All patients but one were initially treated with steroids; three cases with ocular involvement were treated with chlorambucil; and three other cases of neuro-Behçet were treated with cyclophosphamide. After a mean follow-up o…

A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.

Prednimustine, an ester of chlorambucil and prednisolone, was evaluated for efficacy and toxicity in a selected group of leukemia patients with a poor prognosis. Disease subsets consisted of patients with acute non-lymphocytic leukemia (ANLL) over age 60; ANLL refractory to standard therapy; smouldering leukemia; and refractory anemia with excess blasts (RAEB). In agreement with previous studies, toxicity from Prednimustine was relatively mild, consisting primarily of infrequent myelosuppression, gastrointestinal side-effects, and mild hyperglycemia. This study did not, however, confirm previo…

Initial therapy of chronic lymphocytic leukemia.

Only chronic lymphocytic leukemia (CLL) patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. Prognostic risk factor profile and comorbidity burden are most relevant for the choice of treatment. For physically fit patients, chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab remains the current standard therapy. For unfit patients, treatment with an anti-CD20 antibody (obinutuzumab or rituximab or ofatumumab) plus milder chemotherapy (chlorambucil) may be applied. Patients with a del(17p) or TP53 mutation should be treated with the k…

Chronic rhinitis: a manifestation of chronic lymphocytic leukemia.

Chronic rhinitis is a condition that occasionally reflects underlying systemic disease. In such cases, physical examination, nasal endoscopy, and computed tomography may be nonspecific. Diagnosis and treatment of the underlying illness may improve nasal symptoms, which may prove refractory to standard rhinitis therapy. A case of chronic rhinitis secondary to nasal involvement of chronic lymphocytic leukemia (CLL) is presented. Biopsy was important in clarifying the cause of the rhinitis. Treatment of the CLL with chlorambucil was successful in alleviating nasal symptoms, and systemic effective…

Simultaneous or spontaneous occurrence of lympho- and myeloproliferative disorders: a report of four cases.

We describe four patients with mixed lympho- and myeloproliferative disorders. One patient had hairy cell leukaemia and acute myelomonocytic … mia 4 years after the diagnosis of chronic lymphocytic leukaemia after only 2 weeks of therapy with chlorambucil. The nuber of cases with concurrent or sequential but spontaneous occurrence of lympho- and myeloproliferative disorders reported so far is now 38. The questions relating to the pathogenesis of the two malignancies are discussed.

[Prolymphocytic and hairy cell leukemias as special forms of chronic lymphatic leukemia].

Cytochemical and immunological studies were performed on "hairy" cells from 5 patients. The results, primarily the detection of surface immu … of ALL and CLL. In both patients the therapeutic results were discouraging with cytostatics (e. g. chlorambucil), splenectomy is considered as the treatment of choice.

[Bestrabucil-induced complete remission in a case of follicular lymphoma, medium-sized cell type, stage IV (leukemic)].

Bestrabucil, a chlorambucil-estradiol conjugate known to accumulate in malignant cells irrespective of the presence or absence of estrogen receptor, was administered to a 41-year-old man with follicular lymphoma, medium-sized cell type (LSG classification) stage IV (leukemic). A daily dose of 100 mg was given for two weeks and then 200 mg for a week. The WBC dropped from 43,100/mm3 with 82% abnormal lymphocytes to 12,800/mm3, and the drug was discontinued. It was resumed two weeks later at a daily dose of 50 mg. Four weeks thereafter, complete remission was obtained with the disappearance of a…

Chronic Lymphocytic Leukaemia (CLL)-Associated Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (PGNMID) Diagnosed in the Absence of Detectable Paraprotein.

Renal involvement in chronic lymphocytic leukaemia (CLL) is uncommon but clinically relevant. We report a man in his early 70s with known CLL who presented with non-nephrotic proteinuria, progressive kidney injury, and hyperkalaemia. Kidney biopsy revealed diffuse membranoproliferative glomerulonephritis with IgG kappa monoclonal deposits on immunofluorescence and electron microscopy, establishing a diagnosis of CLL-associated proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID). Treatment with rituximab and chlorambucil resulted in significant improvement of both …

Прогрессивная многофукальная лейкоэнцефалопатия у пациента с хронической лимфоцитной лейкемией B-клетки после вакцинации COVID-19, осложненная с COVID-19 и мукормикозом: отчет.

: Прогрессивная многофукальная лейкоэнцефалопатия (ПМЛ) представляет собой редкую и фатальную оппортунистичную вирусную болезнь, демиелинизирующую инфекционную болезнь центральной нервной системы (КНС). Существуют различные клинические симптомы заболевания. В настоящем документе представлен клинический пример PML у пациента с лимфоцитической лейкемией B-CLL (B-CLL), который ранее лечился хлорамбучилом, а позднее был запутан с COVID-19 и сукормикозом. ЗАКЛЮЧЕНИЕ: PML может развиваться в режиме клеточной иммунной дисфункции. Поздний диагноз этой болезни, основанный на неконкретных симптомах, явл

Совпадение в аннотации оригинала
BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a rare and fatal opportunistic viral demyelinating infectious disease of the … nical case of PML in a patient with B-Chronic lymphocytic leukemia (B-CLL), previously treated with Chlorambucil, later complicated later with COVID-19 and mucormycosis. CONCLUSION: PML can develop in the setting of cellular immune dysfunction. Late diagnosis of this disease based on nonspecific symptoms is common, therefore when we face a neurological compli …

[Behcet's disease therapy review].

Behçet's disease is an inflammatory process of unknown origin, which usually presents with recurrent oral ulcers, genital aphthae, uveitis a … th immunosuppressive agents as cyclosporin, azathioprine, cyclophosphamide, interferon-alfa-2a, and chlorambucil.

[Non-steroid therapy for sarcoidosis].

Sarcoidosis is a systemic granulomatous disease that the epidemiology remains unknown. The appropriate therapy for sarcoidosis also has not … o corticosteroid. Several cytotoxic agents, including methotrexate, azathioprine, cyclophosphamide, chlorambucil and cyclosporine A, have been used to treat sarcoidosis. There are no studies that have clearly concluded when these agents should be used for treatment. On the basis of safety and efficacy, methotrexate and azathioprine are the preferred drugs. The …

Plasma cell leukemia: a report on three patients.

Three patients with plasma cell leukemia are reported. Two of them has a previous history of myeloma; the third one started with a plasma cell leukemia. Diagnosis was made from the required presence of 20% plasma cells in the peripheral blood. In all 3 cases, bone marrow aspiration and peripheral blood showed plasma cells strongly positive for acid phosphatase and alpha-naphthyl acetate esterase, and negative for periodic acid-Schiff. The first patient was treated with a polychemotherapy regimen that included vincristine, cyclophosphamide, chlorambucil and prednisone, and the second patient wi…

Enhancement by methylxanthines of sister-chromatid exchange frequency induced by cytostatics in normal and leukemic human lymphocytes.

The effect of theobromine (TB) and diphylline (DP) or (1,2-dihydroxy-3-propyl)theophylline on SCE rates induced in vitro by mitomycin C (MMC … combined study, in vivo and in vitro, lymphocytes taken from 2 leukemic patients who had been given chlorambucil (CBC) or Ara-C by injection 3 h before, and then treated with caffeine in vitro, were found to have synergistically increased exchange frequencies.

[Spontaneous septic arthritis in disseminated lupus erythematosus].

The authors report the case of a young 17 year-old girl with acute systemic lupus erythematosus who presented with purulent arthritis due to Group A hemolytic streptococcus in the knee, and perhaps other joints. She had not yet received any treatment. The purulent arthritis was cured by antibiotics. In spite of corticosteroids and immuno-suppressive agents (Chlorambucil), the patient died one year later. Spontaneous purulent arthritis is rare during systemic lupus erythematosus. We found only 8 other cases in the world literature. Contrary to our case, these were patients already treated with …

Sjögren's and plasma cell variant Castleman disease: a case report.

Castleman disease is a rare cause of lymphoid hyperplasia and may result in localized symptoms or an aggressive, multisystem disorder. It ca … h combination chemotherapy and rituximab followed by eighteen months maintenance therapy with pulse chlorambucil and prednisolone and three monthly rituximab.

Nephrotic syndrome due to immunoglobulin M mesangial glomerulonephritis preceding juvenile idiopathic arthritis.

The association between nephrotic syndrome and juvenile idiopathic arthritis have rarely been described in pediatric patients. We report a child with steroid-responsive nephrotic syndrome, with frequent relapses, who presented with a new relapse of nephrotic syndrome associated with arthritis and uveitis at 21 months in remission after treatment with chlorambucil. Juvenile idiopathic arthritis was diagnosed and kidney biopsy examination showed mesangial glomerulonephritis with immunoglobulin M deposits. To our knowledge, only 2 cases of nephrotic syndrome preceding juvenile idiopathic arthriti…